SCHEMBL18044293

SCHEMBL18044293

COc1ccc(-c2ccc(N=Nc3cc(S(=O)(=O)O)c4ccccc4c3N)cn2)cc1

nearest known ligand 0.81

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ APP P05067 1/20 0.63
▸ MAPT P10636 1/20 0.63
▸ THRB P10828 1/20 0.63
▸ HPGD P15428 1/20 0.63
▸ ALOX12 P18054 1/20 0.63
▸ SNCA P37840 1/20 0.63
▸ RECQL P46063 1/20 0.63
▸ BLM P54132 1/20 0.63
▸ KMT2A Q03164 1/20 0.63
▸ TDP1 Q9NUW8 1/20 0.63
▸ SLC7A11 Q9UPY5 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29696999 1.00 MEN1 (0.63) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL15120164 1.00 MEN1 (0.63) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL14988715 0.99 MEN1 (0.62) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL14988718 0.99 MEN1 (0.62) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL15120171 0.91 SLC7A11 (0.58) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL29697114 0.91 SLC7A11 (0.58) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL18044209 0.91 SLC7A11 (0.58) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL14988410 0.90 SLC7A11 (0.57) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL14988413 0.90 SLC7A11 (0.57) MEN1ALDH1A1APPMAPTTHRB
SCHEMBL15120166 0.90 MEN1 (0.60) MEN1ALDH1A1APPMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057823-A1 COMPOSITION FOR IMPROVING CARDIAC FUNCTION KYOTO UNIVERSITY (JP) 2025-02-20 — — US claimed
EP-4454648-A1 COMPOSITION FOR IMPROVING HEART FUNCTION Kyoto University (JP) 2024-10-30 — — EP claimed
US-20240216397-A1 COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY KYOTO UNIVERSITY (JP) 2024-07-04 — — US claimed
US-12011438-B2 Composition for protecting cardiomyocyte KYOTO UNIVERSITY (JP) 2024-06-18 — — US claimed
EP-4331589-A1 COMPOSITION FOR AMELIORATING ABNORMALITY OF SKIN TISSUE Kyoto University (JP) 2024-03-06 — — EP claimed
WO-2023140242-A1 COMPOSITION FOR PROTECTING TISSUE ISOLATED FROM LIVING BODY 国立大学法人京都大学 2023-07-27 — — WO claimed
WO-2023120704-A1 COMPOSITION FOR IMPROVING HEART FUNCTION 国立大学法人京都大学 2023-06-29 — — WO claimed
US-20220401461-A1 Pharmaceutical Composition for Protecting Cartilage KYOTO UNIVERSITY (JP) 2022-12-22 — — US claimed
WO-2022230949-A1 COMPOSITION FOR AMELIORATING ABNORMALITY OF SKIN TISSUE 国立大学法人京都大学 2022-11-03 — — WO claimed
EP-3733177-B1 COMPOSITION FOR PROTECTING CORNEA UNIV KYOTO (JP) 2022-07-06 — — EP claimed
CN-111757733-A Composition for protecting cornea 国立大学法人京都大学 2020-10-09 — — CN claimed
WO-2020027137-A1 MEDICINE COMPOSITION FOR TREATING CEREBRAL INFARCTION 国立大学法人京都大学 2020-02-06 — — WO claimed
WO-2019203176-A1 PHARMACEUTICAL COMPOSITION FOR PROTECTING MYOCARDIAL CELLS 国立大学法人京都大学 2019-10-24 — — WO claimed
EP-3042658-B1 MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE UNIV KYOTO (JP) 2019-01-16 — — EP claimed
EP-2959903-B1 MEDICINE FOR TREATING EYE DISEASE UNIV KYOTO (JP) 2018-10-03 — — EP claimed
US-9931351-B2 Method for improving leptin resistance KYOTO UNIVERSITY (JP) 2018-04-03 — — US claimed
US-9782420-B2 Method for treating eye diseases KYOTO UNIVERSITY (JP) 2017-10-10 — — US claimed
US-9573887-B2 Naphthalene derivative DAITO CHEMIX CORPORATION (JP) 2017-02-21 — — US claimed
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance KYOTO UNIVERSITY (JP) 2016-10-20 — — US claimed
EP-2599771-B1 NAPHTHALENE DERIVATIVE DAITO CHEMIX CORP (JP) 2016-09-14 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057823-A1 COMPOSITION FOR IMPROVING CARDIAC FUNCTION TNNI3, NPPA, TNNT2 MEN1 3615/4885ALDH1A1 978/4885APP 2418/4885
US-12011438-B2 Composition for protecting cardiomyocyte TNNI3, TNNT2, TNNC1 MEN1 3032/4885ALDH1A1 1014/4885APP 3236/4885
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance LIPC, ADIPOR1, GPR119 MEN1 1433/4885ALDH1A1 574/4885APP 757/4885
US-20220401461-A1 Pharmaceutical Composition for Protecting Cartilage COL2A1, MATR3, COL1A1 MEN1 3178/4885ALDH1A1 327/4885APP 3355/4885
US-20240216397-A1 COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY CUTA, FABP4, MMP13 MEN1 4800/4885ALDH1A1 608/4885APP 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback